Peptilogics to Participate in Musculoskeletal Infection Society (MSIS) 32nd Annual Open Scientific Meeting in Pittsburgh
Retrieved on:
Tuesday, August 2, 2022
Health, Surgery, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, KNEA, Algorithm, Knowledge, Infection, World, Education, Phenotype, University, Bone, Mortality, UPMC, MSIS, Orthopedic surgery, Research, Twitter, Health, Associate, Artificial intelligence, Pinnacle, Founders Fund, World Health Organization, Hospital, Biological engineering, Ageing, Technology, Cancer, Patient, LinkedIn, Therapy, Death, National Association Medical Staff Services, Korea Disease Control and Prevention Agency, UPMC Magee-Womens Hospital, Cystic Fibrosis Foundation, Center, QIDP, Cystic fibrosis, Pharmaceutical industry, Wellcome
Peptilogics, a biotech company engineering peptide therapeutics to improve the treatment landscape for patients with life-threatening diseases, will participate in the Musculoskeletal Infection Society (MSIS) 32nd Annual Open Scientific Meeting taking place in Pittsburgh August 5-6.
Key Points:
- Peptilogics, a biotech company engineering peptide therapeutics to improve the treatment landscape for patients with life-threatening diseases, will participate in the Musculoskeletal Infection Society (MSIS) 32nd Annual Open Scientific Meeting taking place in Pittsburgh August 5-6.
- With MSIS taking place in Pittsburgh this year, Peptilogics is hosting an opening night reception Thursday, August 4th.
- As an orthopedic surgeon, I am thrilled to see and work on desperately needed new treatment options such as Peptilogics PLG0206 in preclinical and clinical development.
- PLG0206 represents an important alternative to traditional antibiotic treatments that have limited effectiveness in treating these infections.